The Swiss drugmaker has plucked an experienced scientist from Down Under to lead its early research efforts.
Roche named hematologist Mark Dawson, an expert in cancer epigenetics, to lead its pharma research and early development unit effective May 1.
Why it mattersRoche hiring Mark Dawson to lead early research signals stronger cancer epigenetics prioritization, adjust partnership strategies.